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could not be completely released. These shortcomings were addressed by redesigning
the catheter tip.
Results: Nine patients underwent an uneventful procedure without conversion and
reached the primary 30-day endpoint. Mean procedure time was 101±21min, contrast
dye exposition was 135±73ml and post-dilatation was necessary in 3 patients. After
one year maximal and minimal valve gradients were 15.7±4.8 and 7.5±1.6 mmHg,
respectively. None of the patients had more than trivial paravalvular leak, none needed
pacemaker implantation. After follow-up of 389±195 days, three patients died on none
valve related causes.
Conclusion: After redesign of the delivery system the JenaValveTM AVR System
allowed safe and precise anatomical valve implantation with good valve performance
and no atrioventricular block up to one year after implantation.
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Background: Balloon aortic valvuloplasty (BAV) is currently recommended as an
indispensable step before transcatheter aortic valve replacement (TAVR), in order to
facilitate crossing of the stenotic native valve and to provide adequate positioning and
expansion of a bioprosthesis. However, BAV is not a risk-free procedure, and might
be associated with aortic dissection, stroke, severe aortic regurgitation and conduction
disturbances. We aimed to describe our preliminary experience in TAVR with a self-
expandable prosthesis (CoreValve®, Medtronic Inc.) performed without BAV.
Methods: Single-center, prospective, non-randomized registry of consecutive pts
selected from Sept/09 to Apr/11 to TAVR with TEE monitoring. Pts were divided in
groups accordingly to BAV utilization (A: without BAV and B: with BAV). Procedure
success and clinical outcomes (VARC) were determined, and mean/max gradients,
valve area and expansion and severity of aortic regurgitation after TAVR were analysed
by TEE.
Results: A total of 50 pts were enrolled. Mean age was 82.3 ± 1.4 yrs, 71% were
female, STS score was 11.2 ± 3.4 and logistic Euroscore was 26.8 ± 8.4%. Twenty-
one pts were initially scheduled to TAVR without predilation, and 29 pts to TAVR with
BAV. In 3 pts scheduled to TAVR without BAV (all with LVEF <40% and aortic valve
area <0.7 cm2), severe hypotension occurred after crossing the stenotic valve with the
18F delivery system, and BAV was required. No clinical and anatomic differences (as
determined by TEE and CTA) were observed between groups. Balloon post-dilation
was performed in 7 pts (39%) in group A and in 9 pts (28%) in B. No significant
differences in clinical outcomes were noted. TTE/TEE measurements after TAVR were
shown below.
Conclusion: In this pilot study, TAVR with a self-expandable prosthesis performed
without BAV was feasible and resulted in similar performance as compared to currently
recommended TAVR with predilation. The possibility of hemodynamic disturbance
(particularly in pts with depressed LV function and critically reduced aortic valve area)
should not be overlooked.
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Background: The impact of CT-scan on Post-procedural aortic regurgitation (AR) still
remains controversial. The purpose of this study was to identify the predictors for post-
procedural AR including CT-scan indices.
Methods: Among 337 consecutive TAVI cases in our institution, cardiac CT-scan to
asses precisely the annulus size was performed in the last 109 cases. The CT-measured
mean annulus diameter was calculated as: mDiam-CT=2√(annulus surface/√). The
clinical, echographic and CT-scan characteristics were to identify the predictors for
post-procedural AR ≥2.
Results: Patients were 83.5±5.8 years old with a logistic Euroscore of 23.9±11.5%.
The Edwards valve was used in 92 cases (23mm in 32%, 26mm 58% and 29mm 19%)
and Corevalve in 17 (26mm in 29% and 29mm in 71%). Univariate analysis identified
lower body mass index (25.0±3.8 vs 26.1±4.6, p=0.048), smaller aortic valve area
(0.56±0.13 vs 0.62±0.15, p=0.002), lower grade of pre-procedural AR (0.73±0.71 vs
0.93±0.71, p=0.033), a smaller valve diameter/mDiam-CT ratio” (1.08±0.07 vs
1.12±0.06, p=0.008) and valve diameter/largest Diam-CT ratio” (0.97±0.07 vs
1.01±0.06, p=0.018), transapical approach (22.7 vs 35.7%, p=0.019) and transaortic
approach (0 vs 5.1%, p<0.001) significantly associated with post-procedural AR ≥2.
Calcification score of annulus and valve by CT, “the valve / smallest Diam-CT ratio”
and “the valve / Diam-TEE ratio” were not associated with post-procedural AR.
Multivariate analysis revealed “the valve / mDiam-CT ratio” to be the only independent
predictor for post-procedural AR ≥2 (HR 0.909 by increase of 0.01, 95%CI: 0.837-
0.987, p=0.023). A valve / mDiam-CT ratio threshold of 1.10 (AUC=0.688) predicted
a higher rate of post-procedural AR ≥2 (29.8% vs 11.3%, p=0.015).
Conclusion: The ratio between valve size / mDiam-CT was more accurate than Diam-
TEE to predict post-procedural AR. Further application of CT-scan may decrease the
risk of AR.
TCT-734
Predictors and Clinical Outcome of Patients with Acute Kidney Injury
Following Trans-Cutaneous Aortic Valve Replacement
Israel M Barbash, Itsik Ben-Dor, Gabriel Maluenda, Paul J Corso, Steven A
Goldstein, Zuyue Wang, Rebecca Torguson, Lowell F Satler, Augusto D Pichard, Ron
Waksman
Cardiology Dept., Washington Hospital Center, Washington, DC
Background: Post-procedural acute kidney injury (AKI) is a poor prognostic factor.
Data on incidence and prognostic impact of AKI post-TAVR are scarce and ranges
from 19-28%. Our aim was to identify predictors and assess the prognostic effect of
AKI post-TAVR.
Methods: Consecutive aortic stenosis patients undergoing TAVR (trans-femoral,
n=103; trans-apical (TA), n=47) were retrospectively analyzed. Post-TAVR AKI was
defined as increase in serum creatinine ≥0.3 mg/dL or ≥ X1.5 (<72 hrs) (VARC
definition) or >25% reduction in GFR (MDRD) (<48 hrs) (GFR) as compared with
baseline.
Results: Post-TAVR AKI occurred in 22 (14.6%) of the patients (according to VARC),
and in 11 (7.3%) patients (according to GFR). At discharge, creatinine levels
normalized in 15 (68%) of the patients. Two patients (1.3%) required temporary renal
replacement therapy. Demographics of patients who developed AKI were comparable
to Non-AKI patients. (Table) AKI patients were more likely to have TA TAVR and
general anesthesia (Table). In multivariable analysis PVD (OR 2.62, 95%CI 0.95-7.28),
and trans-apical TAVR (OR 2.41, 95%CI 0.88-6.63) showed borderline significance
for association with AKI. AKI patients required longer ICU stay (64 vs. 177 hrs;
p=0.01) and suffered higher in-hospital (4% vs. 27%; p=0.001) and 30-day mortality
(7% vs. 41%; p <0.001).
Conclusion: Even a small (0.3 mg/dL) increase in baseline creatinine post-TAVR is
associated with worse outcome. Patients with PVD who are selected for TA TAVR
should be managed more carefully in order to prevent AKI.
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